OBJECTIVES: Describe Ide-cel and Cilta-cel multiple myeloma (MM) patients' characteristics, indications in the real world setting in EU5 countries and in the US.

METHODS: 11,430 anonymous MM patient charts were reported by onco-haematologists in EU5 countries and in the US in Q4 2022 and Q1 2023.

205 unique patients received an Anti-BCMA CAR T cells treatment.

RESULTS: A total of 205 unique patients were included in the analysis: 119 received Ide-cel in either 3rd (8 patients), 4th (58 patients) or 5th line of therapy (53 patients).

Treatment with Cilta-cel was prescribed in 86 unique patients with 12 in 3rd line, 36 in 4th line and 38 in 5th line.

In the US, 94 patients received an Anti-BCMA CAR T cell, in Europe, 52 in FR, 38 in DE, 9 in ES and 9 in the UK, 3 in IT

Patients' median age is 63.2 years in the Ide-cel group and 64.9 years in the Cilta-cel group. Most patients treated had an ECOG status of 0-1 (82% for Ide-cel and 70% for Cilta-cel), ISS stage was III (high) (61% with Ide-cel and 57% with Cilta-cel) and cytogenetic profile was high risk in 32% with Ide-cel and 32% with Cilta-cel.

At time of treatment initiation, most patients had at least one comorbidity: mild renal failure (28% with Ide-cel and 22% with Cilta-cel), high blood pressure (39% with Ide-cel and 37% with Cilta-cel) or cardiac dysfunction (5% with Ide-cel and 4% with Cilta-cel).

CONCLUSIONS: In this real-world analysis with patients recently treated with either Ide-cel or Cilta-cel for R/R MM, patients characteristics and number of prior lines of therapy were consistent with the population of patients enrolled in the phase II KarMMa and CARTITUDE-1 clinical trials.

Despite recent results of phase III trials (KarMMa-3 and CARTITUDE-4) there is important heterogeneity in treatment use across EU5 countries.